Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova, Inc. (TKNO)
:TKNO
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.26Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 3.05%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong revenue growth and improved cash outflows, but also highlighted challenges such as a decline in Lab Essentials revenue and a significant drop in gross margin due to inventory write-downs. The company has managed to reduce operating expenses significantly, but continues to face a net loss.Company Guidance
During the third quarter 2024 earnings call for Alpha Teknova, the company reported a 17% increase in revenue, reaching $9.6 million compared to $8.2 million in the same period last year. The growth was primarily driven by sales of custom research and clinical-grade reagents to biopharma customers, despite a challenging market environment. The company managed to reduce its quarterly free cash outflow to $2.4 million, the lowest in over three years, and decreased operating expenses by over $9 million annually since the end of 2023. Teknova's Lab Essentials segment reported high single-digit growth, offset by timing-related declines in custom product sales to large life science tools companies. The Clinical Solutions segment saw a 229% increase in revenue to $2.0 million. The company reiterated its 2024 revenue guidance of $35 to $38 million and expects free cash outflow to be less than $16 million for the year, down from a previous estimate of $18 million. Teknova's management expressed confidence in achieving sustainable above-market growth, supported by a stabilized biopharma market and a strong pipeline of clinical customers.Strong Revenue Growth
Reported 17% revenue growth in Q3 2024 compared to the same period last year, with total revenue reaching $9.6 million, up from $8.2 million in Q3 2023.
Increase in Clinical Solutions Revenue
Clinical Solutions revenue was $2.0 million in Q3 2024, a 229% increase from $0.6 million in Q3 2023, driven by an increased number of customers and higher average revenue per customer.
Reduction in Operating Expenses
Operating expenses for Q3 2024 were $7.5 million, down from $10.2 million in Q3 2023, owing to reduced headcount and spending, especially on professional fees.
Improved Free Cash Outflow
Free cash outflow decreased to $2.4 million in Q3 2024, the lowest level since the IPO in the second quarter of 2021, compared to $5.4 million in Q3 2023.
---
TKNO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TKNO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $6.89 | $7.16 | +3.92% |
| Aug 13, 2024 | $3.97 | $3.71 | -6.55% |
| May 13, 2024 | $1.74 | $1.95 | +12.07% |
| Mar 11, 2024 | $3.02 | $2.85 | -5.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alpha Teknova, Inc. (TKNO) report earnings?
Alpha Teknova, Inc. (TKNO) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Alpha Teknova, Inc. (TKNO) earnings time?
Alpha Teknova, Inc. (TKNO) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TKNO EPS forecast?
TKNO EPS forecast for the fiscal quarter 2024 (Q4) is -0.12.
---